ArticleAmerican journal of ophthalmology case reports2026
Intraocular amyloidosis presenting with secondary glaucoma: a clinical-pathologic report and literature review.
Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We describe a case of intraocular amyloidosis presenting as secondary glaucoma, highlighting the clinical presentation and pathologic correlates. We also review the medical literature on all prior reported cases and discuss the diagnostic challenges pertinent to this particular case. Observations: We report the case of a 72-year-old man presenting with medically intractable elevations of intraocular pressure. On clinical examination, the anterior segment was unremarkable, but there were significant vitreous opacities. The patient underwent tube shunt surgery, and a simultaneous aqueous humor biopsy was acellular and nondiagnostic. A subsequent pars plana vitrectomy demonstrated amyloid aggregates on histology. Mass spectrometric analysis revealed that this was transthyretin-type amyloid (ATTR), which is associated with a hereditary mutation in the transthyretin (TTR) gene, yet systemic evaluation was unremarkable, and our patient has not yet chosen to pursue genetic testing. Conclusions and importance: Amyloid can deposit in nearly all ocular tissues, and it should be suspected when common ophthalmological presentations do not respond appropriately to standard medical therapies. The challenge in this case was that the anterior segment examination was unremarkable, which is a relatively uncommon presentation for secondary glaucoma in the setting of intraocular amyloidosis. Furthermore, unlike the vast majority of cases of glaucoma associated with intraocular amyloidosis reported to date, our patient had no family history of amyloidosis, nor was any evidence of systemic amyloidosis found upon screening. Literature review, however, establishes that vitreous amyloidosis is invariably associated with a hereditary transthyretin (TTR) mutation, even in the relatively uncommon cases presenting without any known family history and without any systemic symptoms. In the appropriate circumstances, a low threshold to biopsy is appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.